Literature DB >> 28251075

Intraocular pressure with rebound tonometry and effects of topical intraocular pressure reducing medications in guinea pigs.

Yue Di1, Xiu-Mei Luo2, Tong Qiao3, Na Lu4.   

Abstract

AIM: To investigate the intraocular pressure (IOP) of adult guinea pig eyes with rebound tonometry (RBT), and assess the effects of four distinctive topical IOP reducing medications including Carteolol, Brimonidine, Brinzolamide and Latanoprost.
METHODS: The IOPs of twenty-four 12-week-old guinea pigs (48 eyes) were measured every two hours in one day with RBT as baselines. All the animals were then divided into four groups (Carteolol, Brimonidine, Brinzolamide and Latanaprost groups, n=6). The IOPs were measured and compared to the baseline 1, 2, 3, 5, 7, 9, 15 and 24h after treatment.
RESULTS: The mean baseline IOP of 24 guinea pigs (48 eyes) was 10.3±0.36 mm Hg (6-13 mm Hg) and no binocular significant differences of IOPs were observed (t=1.76, P>0.05). No significant difference of IOP in Carteolol group at each time point was observed before and after treatment (t=1.48, P>0.05). In Brimonidine group, IOP was 2.2±1.9 mm Hg lower than the baseline after one hour (t=3.856, P=0.003) and lasted for one hour. In Brinzolamide group, IOP was 1.4±1.1 mm Hg lower than the baseline after one hour (t=4.53, P=0.001) and lasted for 7h and the IOP declined most at 3h. In Latanaprost group, IOP was 2.1±1.3 mm Hg lower than the baseline after one hour (t=6.11, P=0.001) and lasted for one hour.
CONCLUSION: The IOP of guinea pig eyes is relatively stable compared to human eyes. In four reducing IOP medications, no significant effect of Carteolol is observed. Brinzolamide has the longest duration, while the Brimonidine has the shortest duration and the maximum level of treatment.

Entities:  

Keywords:  Brimonidine; Brinzolamide; Carteolol; Latanoprost; guinea pig; intraocular pressure

Year:  2017        PMID: 28251075      PMCID: PMC5313539          DOI: 10.18240/ijo.2017.02.02

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  32 in total

1.  Agreement of rebound tonometer in measuring intraocular pressure with three types of applanation tonometers.

Authors:  Makoto Nakamura; Urtogtah Darhad; Yasuko Tatsumi; Miyuki Fujioka; Azusa Kusuhara; Hidetaka Maeda; Akira Negi
Journal:  Am J Ophthalmol       Date:  2006-08       Impact factor: 5.258

2.  Radial artery applanation tonometry for continuous non-invasive arterial pressure monitoring in intensive care unit patients: comparison with invasively assessed radial arterial pressure.

Authors:  A S Meidert; W Huber; J N Müller; M Schöfthaler; A Hapfelmeier; N Langwieser; J Y Wagner; F Eyer; R M Schmid; B Saugel
Journal:  Br J Anaesth       Date:  2013-12-18       Impact factor: 9.166

3.  Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits.

Authors:  Masahiro Orihashi; Yuichiro Shima; Hiroshi Tsuneki; Ikuko Kimura
Journal:  Biol Pharm Bull       Date:  2005-01       Impact factor: 2.233

4.  Relationship of central corneal thickness and intraocular pressure by iCare rebound tonometer.

Authors:  Aparna Rao; Mukesh Kumar; B Prakash; Gopal Varshney
Journal:  J Glaucoma       Date:  2014-08       Impact factor: 2.503

5.  Noninvasive measurement of rat intraocular pressure with the Tono-Pen.

Authors:  C G Moore; S T Milne; J C Morrison
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-02       Impact factor: 4.799

6.  The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma.

Authors:  R Stavinohova; J R Newton; C Busse
Journal:  J Small Anim Pract       Date:  2015-09-03       Impact factor: 1.522

7.  Ocular hypotensive effects of anti-glaucoma agents in mice.

Authors:  Takahiro Akaishi; Noriko Odani-Kawabata; Naruhiro Ishida; Masatsugu Nakamura
Journal:  J Ocul Pharmacol Ther       Date:  2009-10       Impact factor: 2.671

8.  Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Authors:  Yasutaka Takagi; Tadashi Nakajima; Atsushi Shimazaki; Masaaki Kageyama; Takeshi Matsugi; Yasushi Matsumura; B'Ann T Gabelt; Paul L Kaufman; Hideaki Hara
Journal:  Exp Eye Res       Date:  2004-04       Impact factor: 3.467

9.  Effect of tetracaine on intraocular pressure in normal and hypertensive rabbit eyes.

Authors:  Ali Asghar Sarchahi; Hooman Bozorgi
Journal:  J Ophthalmic Vis Res       Date:  2012-01

10.  Quantifying optic nerve axons in a cat glaucoma model by a semi-automated targeted counting method.

Authors:  Leandro B C Teixeira; Kevin A Buhr; Owen Bowie; Felicia D Duke; T Michael Nork; Richard R Dubielzig; Gillian J McLellan
Journal:  Mol Vis       Date:  2014-03-28       Impact factor: 2.367

View more
  5 in total

1.  α-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: A pilot study.

Authors:  Yan Liu; Yuexin Wang; Huibin Lv; Xiaodan Jiang; Mingzhou Zhang; Xuemin Li
Journal:  Mol Vis       Date:  2017-11-15       Impact factor: 2.367

2.  Effects of Topical Latanoprost on Intraocular Pressure and Myopia Progression in Young Guinea Pigs.

Authors:  Nevin W El-Nimri; Christine F Wildsoet
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-05-01       Impact factor: 4.799

Review 3.  Species Differences in the Nutrition of Retinal Ganglion Cells among Mammals Frequently Used as Animal Models.

Authors:  Christian Albrecht May
Journal:  Cells       Date:  2019-10-14       Impact factor: 6.600

4.  Comparative intraocular pressure measurements using three different rebound tonometers through in an ex vivo analysis and clinical trials in canine eyes.

Authors:  Jaeho Shim; Seonmi Kang; Yoonji Park; Sunhyo Kim; Seokmin Go; Eunji Lee; Kangmoon Seo
Journal:  Vet Ophthalmol       Date:  2020-06-05       Impact factor: 1.644

Review 5.  Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.

Authors:  Ryan G Strickland; Mary Anne Garner; Alecia K Gross; Christopher A Girkin
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.